PT1257260E - Formulacao de po - Google Patents

Formulacao de po

Info

Publication number
PT1257260E
PT1257260E PT01908465T PT01908465T PT1257260E PT 1257260 E PT1257260 E PT 1257260E PT 01908465 T PT01908465 T PT 01908465T PT 01908465 T PT01908465 T PT 01908465T PT 1257260 E PT1257260 E PT 1257260E
Authority
PT
Portugal
Prior art keywords
excipient
particle size
size distribution
active substance
formulation
Prior art date
Application number
PT01908465T
Other languages
English (en)
Inventor
Hendrikus Gerardus M Heijerman
Petrus Paulus Hendricus
Henderik Willem Frijlink
Anne Haaije De Boer
Original Assignee
Univ Groningen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8171037&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1257260(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Groningen filed Critical Univ Groningen
Publication of PT1257260E publication Critical patent/PT1257260E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0031—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up by bursting or breaking the package, i.e. without cutting or piercing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2206/00—Characteristics of a physical parameter; associated device therefor
    • A61M2206/10—Flow characteristics
    • A61M2206/16—Rotating swirling helical flow, e.g. by tangential inflows

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT01908465T 2000-02-17 2001-02-19 Formulacao de po PT1257260E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00200550A EP1129705A1 (en) 2000-02-17 2000-02-17 Powder formulation for inhalation

Publications (1)

Publication Number Publication Date
PT1257260E true PT1257260E (pt) 2004-12-31

Family

ID=8171037

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01908465T PT1257260E (pt) 2000-02-17 2001-02-19 Formulacao de po

Country Status (7)

Country Link
US (1) US7344734B2 (pt)
EP (2) EP1129705A1 (pt)
AT (1) ATE271383T1 (pt)
AU (1) AU2001236207A1 (pt)
DE (1) DE60104399T2 (pt)
PT (1) PT1257260E (pt)
WO (1) WO2001060341A1 (pt)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
GB9920839D0 (en) 1999-09-04 1999-11-10 Innovata Biomed Ltd Inhaler
AR028746A1 (es) 2000-06-23 2003-05-21 Norton Health Care Ltd Cartucho de dosis previamente medidas para inhalador de polvo seco accionado por la respiracion, el inhalador y un metodo de provision de dosis previamente medidas de polvo seco
US6681768B2 (en) 2001-06-22 2004-01-27 Sofotec Gmbh & Co. Kg Powder formulation disintegrating system and method for dry powder inhalers
DE10129703A1 (de) * 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
GB0128148D0 (en) 2001-11-23 2002-01-16 Innovata Biomed Ltd Assembly
US6923175B2 (en) 2002-03-20 2005-08-02 Mannkind Corporation Inhalation apparatus
US6932082B2 (en) 2002-04-19 2005-08-23 3M Innovative Properties Company Spacer or actuator for inertial removal of the non-respirable fraction of medicinal aerosols
WO2004030659A1 (en) * 2002-09-30 2004-04-15 Acusphere, Inc. Sustained release porous microparticles for inhalation
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1488819A1 (en) 2003-06-16 2004-12-22 Rijksuniversiteit te Groningen Dry powder inhaler and method for pulmonary inhalation of dry powder
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
BRPI0414907A (pt) * 2003-09-30 2006-11-07 Acusphere Inc formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
CA2562386C (en) 2004-04-21 2014-11-18 Innovata Biomed Limited Inhaler
GB0409197D0 (en) 2004-04-24 2004-05-26 Innovata Biomed Ltd Device
SE530006C2 (sv) * 2004-06-18 2008-02-05 Mederio Ag Inhalator som använder balja
DK1786784T3 (da) 2004-08-20 2011-02-14 Mannkind Corp Katalyse af diketopiperazinsyntese
EP2322180B1 (en) 2004-08-23 2015-05-27 MannKind Corporation Diketopiperazine salts for drug delivery
NZ556709A (en) 2005-02-10 2009-09-25 Glaxo Group Ltd Process for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
US8475845B2 (en) 2005-07-15 2013-07-02 Map Pharmaceuticals, Inc. Method of particle formation
US7799344B2 (en) 2005-09-14 2010-09-21 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
CA2631492A1 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
ES2647080T3 (es) 2006-02-22 2017-12-19 Mannkind Corporation Un método para mejorar las propiedades farmacéuticas de micropartículas que comprenden dicetopiperazina y un agente activo
GB0622818D0 (en) * 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
EP2176251B1 (en) 2007-07-21 2012-02-08 Albany Molecular Research, Inc. 5-pyridinone substituted indazoles and pharmaceutical compositions thereof
EP2020249A1 (de) * 2007-08-01 2009-02-04 Boehringer Ingelheim Pharma GmbH & Co. KG Inhalator
US20090324569A1 (en) 2007-11-21 2009-12-31 Decode Genetics Ehf Biaryl pde4 inhibitors for treating inflammatory, cardiovascular and cns disorders
AU2009204048B2 (en) 2008-01-11 2013-08-01 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as MCH antagonists
EP2082769B1 (en) * 2008-01-24 2015-06-03 Vectura Delivery Devices Limited Inhaler
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
ES2929343T3 (es) 2008-06-13 2022-11-28 Mannkind Corp Inhalador de polvo seco accionado por aspiración para la administración de fármacos
EP2609954B1 (en) 2008-06-20 2021-12-29 MannKind Corporation An interactive apparatus for real-time profiling of inhalation efforts
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
GB201020130D0 (en) * 2010-11-26 2011-01-12 Vectura Delivery Devices Ltd Inhaler
GB0818476D0 (en) * 2008-10-09 2008-11-12 Vectura Delivery Device Ltd Inhaler
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
WO2010060876A1 (de) * 2008-11-28 2010-06-03 Boehringer Ingelheim International Gmbh Dispergierverfahren zur bestimmung der partikelhaftkraft
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
JP5874878B2 (ja) 2009-01-26 2016-03-02 イスラエル インスティトゥート フォー バイオロジカル リサーチ 複素二環スピロ化合物又はその薬学的に許容される塩、これらの化合物を含む医薬組成物、および哺乳類のアルツハイマー病及びインスリン抵抗性症候群及び２型糖尿病を治療するための薬剤の調整における、これらの化合物の利用
CA2754595C (en) 2009-03-11 2017-06-27 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
AU2010259943C1 (en) 2009-06-12 2016-03-03 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
DE102009037840B4 (de) * 2009-08-18 2012-08-16 Gamptec Gmbh Inhalationsvorrichtung und Verfahren zur Inhalation eines Wirkstoffs aus einer Kapsel
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
GB0919465D0 (en) * 2009-11-06 2009-12-23 Norton Healthcare Ltd Airflow adaptor for a breath-actuated dry powder inhaler
CN102985125A (zh) 2010-06-21 2013-03-20 曼金德公司 干粉药物输送系统和方法
BR122020008875B8 (pt) 2011-04-01 2022-12-06 Mannkind Corp Embalagem de bolha e método de fabricação de uma embalagem de bolhas
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
AU2012328885B2 (en) 2011-10-24 2017-08-31 Mannkind Corporation Methods and compositions for treating pain
EP2872205B1 (en) 2012-07-12 2017-02-08 MannKind Corporation Dry powder drug delivery systems
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
AU2014228415B2 (en) 2013-03-15 2018-08-09 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
CN105517560A (zh) 2013-07-03 2016-04-20 生物实践研究国际教育联盟 多粘菌素脂质纳米颗粒
BR112016000937A8 (pt) 2013-07-18 2021-06-22 Mannkind Corp formulações farmacêuticas de pó seco, método para a fabricação de uma formulação de pó seco e uso de uma formulação farmacêutica de pó seco
CN105517607A (zh) 2013-08-05 2016-04-20 曼金德公司 吹入设备和方法
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
SG11201700621XA (en) 2014-07-25 2017-02-27 Agency Science Tech & Res Antibiotic compositions for treating bacterial infections
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
EP3212212B1 (en) 2014-10-31 2020-09-23 Monash University Powder formulation
EP3768267A4 (en) 2018-03-20 2022-04-20 Icahn School of Medicine at Mount Sinai KINA INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE
CA3111275A1 (en) 2018-09-06 2020-03-12 Innopharmascreen Inc. Methods and compositions for treatment of asthma or parkinson's disease
AU2019419414A1 (en) 2018-12-31 2023-04-06 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
US12029709B2 (en) 2022-08-11 2024-07-09 De Motu Cordis Pty Ltd Inhalable epinephrine formulation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1242211A (en) * 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
US5048227A (en) * 1988-05-05 1991-09-17 Junya Okubo Method of cultivating agaricus blazei mushroom
DE4140689B4 (de) 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
DE4211475A1 (de) * 1991-12-14 1993-06-17 Asta Medica Ag Pulverinhalator
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9515182D0 (en) * 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
EP0920324B1 (en) * 1996-11-15 2001-06-27 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
GB9626263D0 (en) * 1996-12-18 1997-02-05 Innovata Biomed Ltd Powder inhaler
JP3051073B2 (ja) * 1996-12-20 2000-06-12 住友林業株式会社 抗腫瘍活性物質
SE9700133D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
KR100436202B1 (ko) * 1997-02-12 2004-09-10 아이.엠.비 가부시키 가이샤 아가리쿠스버섯의자실체를배양하기위한인공균상재배방법과인공균상재배용배지및그재배방법에따라얻어진아가리쿠스버섯의자실체
US6465218B1 (en) * 1997-04-08 2002-10-15 Japan Applied Microbiology Research Institute Co., Ltd. Biologically active substance and process of preparing the same
EP0876814A1 (en) 1997-05-07 1998-11-11 "PHARLYSE", Société Anonyme Dry powder inhaler excipient, process for its preparation and pharmaceutical compositions containing it
US5980918A (en) * 1997-10-24 1999-11-09 Brennen Medical, Inc. β-D-glucan topical composition
GB9820746D0 (en) * 1998-09-23 1998-11-18 Pharmax Limited Micronised pharmaceutical compositions
US6120772A (en) * 1998-10-08 2000-09-19 Hitoshi Ito Oral drugs for treating AIDS patients

Also Published As

Publication number Publication date
US20030053960A1 (en) 2003-03-20
EP1257260B1 (en) 2004-07-21
DE60104399T2 (de) 2005-09-08
AU2001236207A1 (en) 2001-08-27
EP1257260A1 (en) 2002-11-20
ATE271383T1 (de) 2004-08-15
US7344734B2 (en) 2008-03-18
DE60104399D1 (de) 2004-08-26
EP1129705A1 (en) 2001-09-05
WO2001060341A1 (en) 2001-08-23

Similar Documents

Publication Publication Date Title
PT1257260E (pt) Formulacao de po
IL114596A0 (en) Pharmaceutical compositions for administration by inhalation
HK1096034A1 (en) A solid dosage form comprising a fibrate
UY27218A1 (es) Formulaciones de polvos para inhalación
GEP20053473B (en) High Potency Dihydroergotamine Compositions
WO2001049274A3 (en) Methods for pulmonary delivery of interleukin-2
RS50008B (sr) Antifungalna oralna kompozicija koja sadrži itrakonazol i postupak za dobijanje iste
HK1076605A1 (en) Formulations
AU7315301A (en) Compounds and compositions for delivering active agents
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
BG104877A (en) N-substituted anminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
EA200000584A2 (ru) Твердые фармацевтические композиции с контролируемым высвобождением, получаемые тепловым формованием
YU68199A (sh) Farmaceutske formulacije koje sadrže vorikonazol
MXPA04007427A (es) Formulaciones de azitromicina granuladas por via seca.
ATE148630T1 (de) Stabilisierte derivate von vitamin d2 und d3 enthaltende pharmazeutische zusammensetzungen
NO20000466L (no) Farmasøytisk preparat for sure, lipofile forbindelser i form av en selvregulerende formulering
MXPA04003027A (es) Metodos para granulacion humeda de azitromicina.
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
PT1195160E (pt) Composições farmacêuticas de trimetazidina de libertação sustentada e método para a sua preparação
WO2005065639A3 (en) Novel pharmaceutical compositions
MXPA02011410A (es) Uso de compuestos 1-amino-5-fenilpentan-3-ol y/o 1-amino-6-fenilhexan-3-ol substituidos como medicamentos.
WO2002020056A3 (en) Methods and compositions for producing a neurosalutary effect in a subject
AU2002220654A1 (en) Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders
ZA200100289B (en) Use of tiludronic acid and derivatives thereof in poultry for the preparation of a medicinal product for preventing and treating osteoporosis.
MY145885A (en) Controlled release formulations for oral administration